# Denosumab

## Prolia inj 60mg

| 藥物代碼 | IPRO6 |
| :--- | :--- |
| 適應症 | Treatment of postmenopausal women w/ osteoporosis at high risk for fracture; bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer; bone loss in men receiving androgen deprivation therapy for prostate cancer. |
| 副作用 | Facial swelling and urticaria have been reported. Influenza, hypocalcemia, headache, lethargy, dyspnea, diarrhea, nausea, dyspepsia, bone pain, arthralgia, myalgia, flu-like symptoms, pyrexia, rigors, fatigue, pain, asthenia. Local site reactions. Osteonecrosis of the jaw.Cardiovascular: Peripheral edema \(Paget's Disease, 3%; osteoporosis, 4.6% to 5.5%; bone metastasis, 21% \)Endocrine metabolic: Weight decreased \(bone metastasis, 16% \)Gastrointestinal: Abdominal pain \(osteoporosis \(female\), 0.9% to 4.6%; osteoporosis \(male\), 7.9%; Paget's disease, 2%; hypercalcemia of malignancy, 16%; bone metastasis, 14% \), Constipation \(Paget's disease, 6%; hypercalcemia of malignancy, 27%; bone metastasis, 31% \), Diarrhea \(osteoporosis, 5.2% to 6%; Paget's disease, 6%; hypercalcemia of malignancy, 17%; bone metastasis, 24% \), Loss of appetite \(osteoporosis, 1% to 2%; Paget's disease, 2%; hypercalcemia of malignancy, 9%; bone metastasis, 22% \), Nausea \(osteoporosis, 4.5% to 8.5%; Paget's disease, 9%; hypercalcemia of malignancy, 29%; bone metastasis, 46% \), Vomiting \(Paget's disease, 2%; osteoporosis, 3.4% to 4.6%; hypercalcemia of malignancy, 14%; bone metastasis, 32% \)Musculoskeletal: Arthralgia \(osteoporosis \(female\), 17.9% to 23.8%; osteoporosis \(male\), 11.1%; hypercalcemia of malignancy, 5% to less than 10%; Paget's disease, 9%; bone metastasis, 21% \), Backache \(Paget's disease, 4%; bone metastasis, 15% \)Neurologic: Asthenia \(osteoporosis, 3.2 to 5.3%; Paget's disease, 2%; bone metastasis, 24% \), Dizziness \(osteoporosis, 2% to 7.6%; Paget's disease, 9%; bone metastasis, 18% \), Headache \(osteoporosis \(female\), 3.9% to 12.4%; osteoporosis \(male\), 15%; Paget's disease, 11%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 19% \), Insomnia \(hypercalcemia of malignancy, 15%; bone metastasis, 16% \), Paresthesia \(Paget's disease, 2%; bone metastasis, 15% .\)Renal: Nephrotoxicity \(bone metastasis, 11% to 17% \)Other: Fatigue \(osteoporosis \(female\), 2.1% to 5.4%; osteoporosis \(male\), 17.6%; Paget's disease, 8%; bone metastasis, 39% \), Fever \(osteoporosis \(female\), 7% to 18%; osteoporosis \(male\), 15.7%; Paget's disease, 3% to 11%; hypercalcemia of malignancy, 44%; bone metastasis, 32% \) |
| 禁忌 | Hypocalcemia. Pregnancy & lactation. Severe renal impairment. Hypersensitivity to any component of the product; facial swelling and urticaria have been reported. |
| 藥物保存方式 | 2-8℃ |
| 用法用量 | 60 mg SC as a single dose, once every 6 months. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | \[仿單\]有生育能力之婦女於治療期間至最後一劑藥物後五個月內,應採有效的避孕措施. |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 注射前於冰箱取出，可於室溫擺放15-30分鐘回溫，本藥品不可加熱。 2. 皮下注射部位：上臂、上臀或腹部。 |

